Agomelatine Suppliers & Bulk Manufacturers
Available Forms: Tablets
Available Strengths: 25 mg, 50 mg
Reference Brands: Valdoxan (EU/UK), Thymanax (India/ Middle East)
Category:
Psychiatry / Mental Health
Agomelatine is available in Tablets
and strengths such as 25 mg, 50 mg.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Agomelatine is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Agomelatine can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Agomelatine is a novel antidepressant with a unique mechanism of action, functioning as a melatonergic agonist and a 5-HT2C antagonist. This dual activity helps regulate the sleep-wake cycle and improves mood by promoting the release of norepinephrine and dopamine in the brain. It is primarily used to treat major depressive disorder (MDD) in adults, offering benefits for both psychiatric and primary care patients who have not achieved full remission with conventional antidepressants.
One of the distinguishing features of agomelatine is its favorable side-effect profile. It is generally well-tolerated, with minimal risk of sexual dysfunction, weight gain, or discontinuation syndrome, and it is relatively safe in cases of overdose. However, a small percentage of patients may experience elevated liver enzymes, which requires monitoring during treatment. Agomelatine’s ability to improve sleep patterns while alleviating depressive symptoms makes it a promising option for patients struggling with persistent depression. With further clinical evaluation, it may become a valuable addition to the available pharmacological strategies for managing depression in diverse healthcare settings.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing